Navigation Links
StemCor Systems Receives CE Mark for MarrowMiner(TM) System for Bone Marrow Collection
Date:9/10/2008

Receipt of CE Mark Clears the Way for Commercialization in the European

Union

MENLO PARK, Calif., Sept. 10 /PRNewswire/ -- StemCor Systems, Inc., a medical device company developing systems for Enabling Regenerative Medicine(TM), announced today that the Company has received the CE (Conformite European) Mark for its MarrowMiner System. The MarrowMiner System is a minimally invasive device used to harvest adult stem cells from the ilium (pelvis), and represents next-generation technology for use in bone marrow transplants, for accelerating bone healing in spinal fusions and other orthopedic procedures, and an expanding array of clinical applications utilizing bone marrow-derived cells. The CE Mark indicates that the product complies with the appropriate quality and safety standards to be commercialized in the EU, and furthers StemCor's goal of becoming a global company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071030/STEMCORSYSTEMSLOGO)

"We are excited that this regulatory authorization gives us the ability to commercialize StemCor Systems' technology in the European Union. The use of adult-derived stems cells is expanding rapidly, especially in spine fusion and other orthopedic procedures. We are pleased to be able to offer this novel device to physicians outside of the US, whereby bone marrow can be harvested in a more facile and relatively atraumatic way compared to traditional methods," said Vartan Ghazarossian, Ph.D., President and CEO of StemCor Systems.

About the MarrowMiner

The proprietary MarrowMiner System is designed to rapidly and easily harvest bone marrow in a minimally invasive manner, in the outpatient setting, and without general anesthesia. The System consists of an access guide, a powered handle that drives a flexible atraumatic shaft through which marrow is aspirated, and an in
'/>"/>

SOURCE StemCor Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
2. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
3. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
4. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
5. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
9. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
10. PLC Systems Reports Fourth Quarter 2007 Results
11. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , RICHMOND, Va., Nov. 30 /PRNewswire/ -...icense with sanofi-aventis U.S. for a novel epinep...ory. Under the license, sanofi-aventis U.S. shall ...tion. Intelliject will be responsible for the on-g... approval and has retained certain co-promotion ri...
(Date:11/30/2009)..., , ATLANTA, G...College of,Direct Support (CDS), an internet-based...anaged in partnership by MC Strategies/Elsevier an...ining Center, announced today that,its second Disa...is now,available for administrators and learners t...
(Date:11/29/2009)..., , CHICAGO, Nov. 30 Middl...physical activity may be unknowingly causing damag...eoarthritis, according to a study presented today ...of North America (RSNA). ,, "Our data suggest t...y be at greater risk for developing knee abnormali...
Breaking Medicine Technology:Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector 2Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector 3Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering 2Cerebral Palsy Course Strengthens CDS Curriculum as Second Disability Intensive Course Offering 3Too Much Physical Activity May Lead to Arthritis 2Too Much Physical Activity May Lead to Arthritis 3Female Supervisors More Likely to Be Sexually Harassed 54300 1Female Supervisors More Likely to Be Sexually Harassed 54300 2Female Supervisors More Likely to Be Sexually Harassed 54300 3September is Prostate Cancer Awareness Month 54295 1September is Prostate Cancer Awareness Month 54295 2Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 54292 1Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 54292 2
...il 29 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA... clinical trial of AZ-007 (Staccato(R) zaleplon). ...veloped for the treatment of insomnia,patients who...s who awake,in the middle of the night and have di... product candidate using our single-dose Staccato,...
...and multi-lesion clinical trial data to be pre..., May 13, MENLO PARK, Calif., April 28 XTENT, In...ts for the first quarter ended,March 31, 2008., T...r $0.54 per share,for the first quarter of 2008, c...r share, for the first quarter of 2007. The compan...
Other Medicine Technology:Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 2Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 3Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 4XTENT Announces First Quarter 2008 Financial Results 2XTENT Announces First Quarter 2008 Financial Results 3XTENT Announces First Quarter 2008 Financial Results 4XTENT Announces First Quarter 2008 Financial Results 5
(Date:11/30/2009)...Finding and treating a tumor without disturbing no...t effective therapies can be invasive and harsh. ,...ave devised a way they might deliver the right the...alled aptamers, which specifically bind to living ...tamers in a rodent with liver cancer until they fo...
(Date:11/30/2009)... According to Steven McConnell, DDS, teac...ng flu season is a good idea, but brushing their t...ally coming down with a virus. , ...the California Dental Hygienists’ Associatio...ween oral health and flu prevention because the H1...
(Date:11/30/2009)...AGO, Nov. 30 Three decades ago, a ...ing swallowed by children, prompting a switch by U...ted today at the annual meeting of the Radiologica...ew tabs are still potentially unsafe. ,, "One o...ge can construction in the U.S. was to eliminate i...
(Date:11/30/2009)... decades ago, a study revealed that beverage can p...ng a switch by U.S. manufacturers to stay-tabs. Bu... the Radiological Society of North America (RSNA) ...fe. , "One of the driving factors leading the ch...to eliminate inadvertent swallowing of the pull-ta...
(Date:11/29/2009)... Moravia,s Nanjing-based Service Delivery...e , Brno, Czech Republic ...ion solution provider, is pleased to announce its ...2009, to be held in Nanjing, China, on November 30...nion-based companies that have established and gro...
Breaking Medicine News(10 mins):Health News:First live targeting of tumors with RNA-based technology 2Health News:First live targeting of tumors with RNA-based technology 3Health News:Tips on Decreasing Susceptibility to the H1N1 Virus - Optimum Oral Hygiene Can Prevent Flu 2Health News:Tips on Decreasing Susceptibility to the H1N1 Virus - Optimum Oral Hygiene Can Prevent Flu 3Health News:Tips on Decreasing Susceptibility to the H1N1 Virus - Optimum Oral Hygiene Can Prevent Flu 4Health News:Beverage Can Stay-Tabs Pose Swallowing Risk 2Health News:Beverage can stay-tabs pose swallowing risk 2Health News:Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China 2
...previously noted low rates of successful hepatitis... large part due to very early differences in the a...y is published in the April 15 issue of the Journ...f the population is infected. Chronic HCV infectio...
...ups, survival odds after angioplasty are not as gr...-- A major international study pinpoints which peo...ter off having bypass surgery than artery-opening ...cy and cardiovascular medicine at Stanford Univers...
...ng Helps Mainstream Management Process , , STUART... Health Systems, a not-for-profit, community-based...Florida, needed a way to track potential conflicts...ncommon for outside interests and business prospec...
...ta Barbara, California, offshore oil spill gave bi... States a leader in environmental protection world...n a key issue to both industrial and environmental...ciety. , In his new book, The Conflict over Envi...
...e Savvy Self-Funding Healthcare Conference and Exp...the opportunity to discuss creative healthcare opt...City, Missouri. , , This unique conference is des...nt to help educate employers and plan sponsors on ...
...versity, together with colleagues at the Karolinsk...nd all the genes the determine the dosage of the b...ished in the scientific journal PLoS Genetics . ,...he two most important genes are among those we pre...
Other Medicine News:Health News:2-day results predict ultimate response to therapy in chronic hepatitis C 2Health News:Diabetics and Elderly May Fare Better With Bypass 2Health News:Diabetics and Elderly May Fare Better With Bypass 3Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 2Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 3Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 4Health News:MediTract's Compliance Management Tools Improve Efficiencies at Martin Memorial Health Systems 5Health News:An even-handed analysis of environmental policy 2Health News:Deffenbaugh Industries to Host Self-Funding Healthcare Conference in Kansas City 2
Replacement Bulb: HBO 100W/2
Replacement Bulb: FCS
Replacement Bulb: ELH
Replacement Bulb: EJA
Medicine Products: